Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
about
Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonanceNoninvasive imaging of cardiovascular injury related to the treatment of cancerAggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicinCardiac complications of chemotherapy: role of imaging.Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography.Cardiotoxicity of cancer therapy.Early Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study.Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.The utility of cardiac stress testing for detection of cardiovascular disease in breast cancer survivors: a systematic review.Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variablesUtility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancerVentricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant ChemotherapyAnthracycline cardiotoxicity.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Anthracycline-Induced Cardiomyopathy in Adults.Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.Echocardiography and Alternative Cardiac Imaging Strategies for Long-Term Cardiotoxicity Surveillance of Cancer Survivors Treated with Chemotherapy and/or Radiation Exposure.Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy.Protecting the heart in cancer therapy
P2860
Q26859193-FA964DBC-6B10-432C-A500-B9F996BFDE4FQ27024715-5727FD8A-8C03-43DD-AF72-2C48226B82D9Q28368331-B27D6FA8-8094-4C6A-8639-98520C2EC9BFQ30415201-28282590-68F2-4364-9B37-E4A9D8A5CF1CQ30427656-0F789BED-FF58-4417-9AA9-1FE17D6CBA67Q30446509-0892D4C4-4B1A-4228-8407-D3C3688E2A57Q30491590-F18FFA9B-375B-4683-BCEA-D42CC5F15FDBQ33704056-4DAC5D54-3A4A-4C1A-BF0E-84E22A353812Q33752979-3FF044D3-C1E6-4FF9-91F5-737188F58C0AQ34037001-CCBC5E16-4649-4B57-98E7-66E2E328D8C2Q34659375-EDBE5C09-4636-4D6A-8719-942ACE8504AFQ35043809-4AF26DAA-216D-4523-A8AB-D4F163D45791Q35371321-F96809FF-EEBC-4F4E-B4F1-25A5F519AA29Q35905883-A491F795-EB74-4449-9700-A87782B478EAQ36332458-FC7E76BA-FD96-46DD-B8BE-C0CE5A03E1F2Q36431196-3CBF0BDC-8094-4ADE-B957-542103426CAEQ36558438-7C5BCE4A-D120-4F05-B705-4613D965D1BFQ36624983-3E3BBE81-5F50-4D16-B754-307B6395E0D8Q38166071-7C44E48D-EC1E-4858-848F-44FBE327C4D8Q38542462-23159CFE-A83C-4FEC-BAE1-944D4FCE6B0CQ38559474-E37C229B-4122-4896-BEE3-001DB0392F64Q38868285-9478A9BE-0018-4AB4-86B8-B1043B3CD72FQ38909573-A9F606A5-1D77-455D-9091-267F5E678EE5Q43199588-4885FB30-5370-426C-B423-5C2756C97E9BQ57821006-4171BDD8-2E4A-4D4A-AA2C-3DB7A2100CC6
P2860
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
Sensitivity and specificity of ...... in doxorubicin cardiotoxicity.
@en
Sensitivity and specificity of ...... in doxorubicin cardiotoxicity.
@nl
type
label
Sensitivity and specificity of ...... in doxorubicin cardiotoxicity.
@en
Sensitivity and specificity of ...... in doxorubicin cardiotoxicity.
@nl
prefLabel
Sensitivity and specificity of ...... in doxorubicin cardiotoxicity.
@en
Sensitivity and specificity of ...... in doxorubicin cardiotoxicity.
@nl
P2093
P1476
Sensitivity and specificity of ...... in doxorubicin cardiotoxicity.
@en
P2093
Billingham ME
Bockemuehl K
Bristow MR
McKillop JH
P304
P356
10.1016/0002-8703(83)90651-8
P407
P433
P577
1983-11-01T00:00:00Z